Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891868538> ?p ?o ?g. }
- W2891868538 endingPage "82" @default.
- W2891868538 startingPage "82" @default.
- W2891868538 abstract "Naltrexone and naloxone are classical opioid antagonists. In substantially lower than standard doses, they exert different pharmacodynamics. Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opioid-receptor blockade. Clinical reports of LDN have demonstrated possible benefits in diseases such as fibromyalgia, Crohn's disease, multiple sclerosis, complex-regional pain syndrome, Hailey-Hailey disease, and cancer. In a dosing range at less than 1 μg per day, oral naltrexone or intravenous naloxone potentiate opioid analgesia by acting on filamin A, a scaffolding protein involved in μ-opioid receptor signaling. This dose is termed ultra low-dose naltrexone/naloxone (ULDN). It has been of use in postoperative control of analgesia by reducing the need for the total amount of opioids following surgery, as well as ameliorating certain side-effects of opioid-related treatment. A dosing range between 1 μg and 1 mg comprises very low-dose naltrexone (VLDN), which has primarily been used as an experimental adjunct treatment for boosting tolerability of opioid-weaning methadone taper. In general, all of the low-dose features regarding naltrexone and naloxone have been only recently and still scarcely scientifically evaluated. This review aims to present an overview of the current knowledge on these topics and summarize the key findings published in peer-review sources. The existing potential of LDN, VLDN, and ULDN for various areas of biomedicine has still not been thoroughly and comprehensively addressed." @default.
- W2891868538 created "2018-09-27" @default.
- W2891868538 creator A5021023560 @default.
- W2891868538 creator A5054533966 @default.
- W2891868538 date "2018-09-21" @default.
- W2891868538 modified "2023-10-12" @default.
- W2891868538 title "Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization" @default.
- W2891868538 cites W1727378690 @default.
- W2891868538 cites W1850379830 @default.
- W2891868538 cites W1889480724 @default.
- W2891868538 cites W1930742983 @default.
- W2891868538 cites W1963985457 @default.
- W2891868538 cites W1966222552 @default.
- W2891868538 cites W1969913876 @default.
- W2891868538 cites W1969966959 @default.
- W2891868538 cites W1971825677 @default.
- W2891868538 cites W1973823807 @default.
- W2891868538 cites W1982170042 @default.
- W2891868538 cites W1984806469 @default.
- W2891868538 cites W1985971916 @default.
- W2891868538 cites W1988132987 @default.
- W2891868538 cites W1992267320 @default.
- W2891868538 cites W1993639810 @default.
- W2891868538 cites W1994291650 @default.
- W2891868538 cites W1995317457 @default.
- W2891868538 cites W2000069076 @default.
- W2891868538 cites W2000388826 @default.
- W2891868538 cites W2000824762 @default.
- W2891868538 cites W2003883053 @default.
- W2891868538 cites W2007417658 @default.
- W2891868538 cites W2007659283 @default.
- W2891868538 cites W2010823692 @default.
- W2891868538 cites W2012622720 @default.
- W2891868538 cites W2027562529 @default.
- W2891868538 cites W2030520122 @default.
- W2891868538 cites W2030877933 @default.
- W2891868538 cites W2043354325 @default.
- W2891868538 cites W2045406685 @default.
- W2891868538 cites W2047395646 @default.
- W2891868538 cites W2049608435 @default.
- W2891868538 cites W2059538358 @default.
- W2891868538 cites W2071801806 @default.
- W2891868538 cites W2080977352 @default.
- W2891868538 cites W2085662515 @default.
- W2891868538 cites W2088795854 @default.
- W2891868538 cites W2091235395 @default.
- W2891868538 cites W2095902657 @default.
- W2891868538 cites W2096615733 @default.
- W2891868538 cites W2101540330 @default.
- W2891868538 cites W2108163830 @default.
- W2891868538 cites W2113754496 @default.
- W2891868538 cites W2115960901 @default.
- W2891868538 cites W2116093385 @default.
- W2891868538 cites W2120463963 @default.
- W2891868538 cites W2121286031 @default.
- W2891868538 cites W2126241051 @default.
- W2891868538 cites W2128132289 @default.
- W2891868538 cites W2132854289 @default.
- W2891868538 cites W2134716133 @default.
- W2891868538 cites W2137894294 @default.
- W2891868538 cites W2138380096 @default.
- W2891868538 cites W2145783290 @default.
- W2891868538 cites W2149900193 @default.
- W2891868538 cites W2155347146 @default.
- W2891868538 cites W2155786710 @default.
- W2891868538 cites W2160053949 @default.
- W2891868538 cites W2165305033 @default.
- W2891868538 cites W2171795872 @default.
- W2891868538 cites W2194372581 @default.
- W2891868538 cites W2239029086 @default.
- W2891868538 cites W2287810847 @default.
- W2891868538 cites W2344382441 @default.
- W2891868538 cites W2402997432 @default.
- W2891868538 cites W2404283831 @default.
- W2891868538 cites W2412243856 @default.
- W2891868538 cites W2418405651 @default.
- W2891868538 cites W2419428049 @default.
- W2891868538 cites W2460276671 @default.
- W2891868538 cites W2523773158 @default.
- W2891868538 cites W2525660953 @default.
- W2891868538 cites W2528322242 @default.
- W2891868538 cites W2529411537 @default.
- W2891868538 cites W2607401549 @default.
- W2891868538 cites W2740763482 @default.
- W2891868538 cites W2741640244 @default.
- W2891868538 cites W2761768545 @default.
- W2891868538 cites W2783170063 @default.
- W2891868538 cites W2783722146 @default.
- W2891868538 cites W2790175340 @default.
- W2891868538 cites W2792368473 @default.
- W2891868538 cites W2792609405 @default.
- W2891868538 cites W2803245866 @default.
- W2891868538 cites W2807702373 @default.
- W2891868538 cites W2947560189 @default.
- W2891868538 cites W4230403072 @default.
- W2891868538 cites W4233403863 @default.
- W2891868538 cites W4295677765 @default.
- W2891868538 cites W2766354756 @default.